Selective RAF inhibitor impairs ERK 1/2 phosphorylation and growth in mutant NRAS, vemurafenib‐resistant melanoma cells
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Summary: The RAF inhibitor vemurafenib achieves remarkable clinical responses in mutant BRAF melanoma patients. However, vemurafenib is burdened by acquired drug resistance and by the side effects associated with its paradoxical activation of the ERK 1/2 pathway in wild‐type BRAF cells. This paradoxical effect has driven the development of a new class of RAF inhibitors. Here, we tested one of these selective, non‐paradox‐inducing RAF inhibitors termed paradox‐breaker‐04 (PB 04) or PLX 7904. Consistent with its design, PB 04 is able to efficiently inhibit activation of ERK 1/2 in mutant BRAF melanoma cells but does not hyperactivate ERK 1/2 in mutant RAS‐expressing cells. Importantly, PB 04 inhibited ERK 1/2 phosphorylation in mutant BRAF melanoma cells with acquired resistance to vemurafenib/PLX 4720 that is mediated by a secondary mutation in NRAS. Consistent with ERK 1/2 reactivation driving the re‐acquisition of malignant properties, PB 04 promoted apoptosis and inhibited entry into S phase and anchorage‐independent growth in mutant N‐RAS‐mediated vemurafenib‐resistant cells. These data indicate that paradox‐breaker RAF inhibitors may be clinically effective as a second‐line option in a cohort of acquired vemurafenib‐resistant patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156 · cited 2×
“In the phase 2 and 3 trials with vemurafenib, approximately 50% of V600 BRAF melanoma patients responded with at least 30% tumor shrinkage (Chapman et al., 2011; Sosman et al., 2012).”
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454 · cited 4×
“Reactivation may be initiated through a secondary mutation in NRAS, expression of splice variant of V600E BRAF, enhanced expression of the alternative MAP3K, COT1/Tpl2, or downstream through secondary mutation in MEK1/2 (Johannessen et al., 2010; Nazarian et al., 2010; Poulikakos et al., 2011).”
InfluentialModelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Das Thakur, M., Salangsang, F., Landman, A. S., Sellers, W. R., Pryer, N. K., Levesque, M. P., Dummer, R., McMahon, M., & Stuart, D. D. (2013) · Nature · doi:10.1038/nature11814 · Cited by 730
Cited by
Regulation of RAF protein kinases in ERK signalling
Lavoie, H., & Therrien, M. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3979 · Cited by 702
RAF-MEK-ERK pathway in cancer evolution and treatment
Ullah, R., Yin, Q., Snell, A. H., & Wan, L. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.010 · Cited by 553
Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations
Dankner, M., Rose, A. A. N., Rajkumar, S., Siegel, P. M., & Watson, I. R. (2018) · Oncogene · doi:10.1038/s41388-018-0171-x · Cited by 550
BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
Rizos, H., Menzies, A. M., Pupo, G. M., Carlino, M. S., Fung, C., Hyman, J., Haydu, L. E., Mijatov, B., Becker, T. M., Boyd, S. C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3122 · Cited by 547
New perspectives for targeting RAF kinase in human cancer
Karoulia, Z., Gavathiotis, E., & Poulikakos, P. I. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.79 · Cited by 404
RAF inhibitors that evade paradoxical MAPK pathway activation
Zhang, C., Spevak, W., Zhang, Y., Burton, E. A., Ma, Y., Habets, G., Zhang, J., Lin, J., Ewing, T., Matusow, B., et al. (2015) · Nature · doi:10.1038/nature14982 · Cited by 382
Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas In Vivo and Ex Vivo
Hartsough, E. J., Kugel, C. H., Vido, M. J., Berger, A. C., Purwin, T. J., Goldberg, A., Davies, M. A., Schiewer, M. J., Knudsen, K. E., Bollag, G., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0705 · Cited by 27
“PLX8394 suppresses ERK1/2 signaling and tumor growth in vivo PLX8394 is a mutant BRAF-selective inhibitor that potently blocks ERK1/2 signaling in BRAF V600E/D–harboringmelanoma cells in vitro (18, 19, 24).”
Self-citation
Metadata
- Authors
- Le, K., Blomain, E. S., Rodeck, U., & Aplin, A. E.
- Venue
- Pigment Cell & Melanoma Research
- Publisher
- Wiley
- Published
- 2013-04-08
- Volume
- 26
- Issue
- 4
- Pages
- 509-517
- ISSN
- 1755-1471 (ISSN-L)
- 1755-148X
- OpenAlex
- W2070819820
- Cited by
- 70
- References
- 5
- FWCI
- 5.78
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.